BioSpace News Archive

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2020 and provided an update on recent developments. Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon has successfully focused on the execution of its ongoing clinical

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMO), today announced plans to significantly expand its biology capabilities at its integrated R&D campus in Hyderabad, India with a dedicated 75,000 sq. ft. facility and an augmented team of 170 biologists.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2020 , on Thursday, November 5, 2020 before the opening of the financial markets.

PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial epilepsy, the high

LifeScan, a world leader in blood glucose monitoring serving 20 million people with diabetes and the maker of the iconic OneTouch® brand, today announced its partnership with Truepill™, the digital health platform powering consumer health experiences through its API-connected infrastructure.

The National Kidney Foundation (NKF) is pleased to announce that Dr. Paul M. Palevsky, a nephrologist and Professor of Medicine, University of Pittsburgh School of Medicine and Chief of Kidney Medicine at the VA Pittsburgh Healthcare System, has begun his two-year term as president of NKF’s Board of Directors.

James Aggen, PhD has joined Circle Pharma as its Vice President of Medicinal Chemistry and will lead Circle’s chemistry team in its discovery and development of macrocycle therapeutics against intractable cancer targets.

Syntropy, a technology company specializing in healthcare data integration and collaboration solutions, today announced it is joining forces with MITRE to provide data integration support for the mCODE™ (minimal Common Oncology Data Elements) data standard.

AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, announced that the company will be participating in two upcoming investor conferences.

– Promising findings featuring XL092, Exelixis’ next-generation oral tyrosine kinase inhibitor, recently presented at the 32 nd EORTC-NCI-AACR (ENA) Symposium –